CA2462510C - Wipe formulation - Google Patents
Wipe formulation Download PDFInfo
- Publication number
- CA2462510C CA2462510C CA2462510A CA2462510A CA2462510C CA 2462510 C CA2462510 C CA 2462510C CA 2462510 A CA2462510 A CA 2462510A CA 2462510 A CA2462510 A CA 2462510A CA 2462510 C CA2462510 C CA 2462510C
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- present
- agent
- amount
- preservative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Abstract
The present invention relates to a liquid formulation for a feminine wipe. The preferred formulation has an anti-irritant agent, a pH adjuster namely citric acid, and at least one preservative.
Description
WIPE FORMULATION
BACKGROUND OF THE INVENTION
1. Field Of The Invention The present invention relates to a formulation for a wipe. More particularly, the present invention relates to a wipe or towelette formulation that has an anti-irritant agent. The wipe is particularly useful for feminine cleansing, and may alternatively be used for adult personal hygiene.
BACKGROUND OF THE INVENTION
1. Field Of The Invention The present invention relates to a formulation for a wipe. More particularly, the present invention relates to a wipe or towelette formulation that has an anti-irritant agent. The wipe is particularly useful for feminine cleansing, and may alternatively be used for adult personal hygiene.
2. Description of the Prior Art A towelette or wipe is generally an absorbent sheet that is treated or pre-moistened with a liquid formulation. The liquid used in pre-moistening the sheet is generally an aqueous solution. The solution may have a surface active detergent, a humectant and, in some instances, also a fragrance.
U.S. Patent No. 5,804,203 to Hahn et al. is directed to a topical composition for reducing skin irritation in animals comprising an irritant ingredient and an anti-irritant amount of aqueous-soluble strontium cation.
U.S. Patent No. 4,772,501 to Johnson et al. is directed to a wet wipe product having a fibrous wipe, a liquid preservative composition, and an 2 0 enclosure for the fibrous wipe and the liquid preservative composition.
The liquid preservative composition consists essentially of: (a) a mixture of citric acid and sorbic acid as the preservative component; (b) water; and (c) optional ingredients selected from the group consisting of skin moisturizers and fragrance compounds.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a mild formulation for use in a wipe.
It is another object of the present invention to provide a mild wipe formulation that has an anti-irritant agent.
It is a further object of the present invention to provide such a mild wipe formulation that prevents or minimizes skin irritation and itching especially feminine itching.
These and other objects and advantages of the present invention are achieved by a mild wipe formulation that comprises an anti-irritant agent, citric acid and at least one preservative. In one embodiment of the present invention, the wipe formulation comprises an anti-irritant agent, a pH adjuster, namely citric acid, at least one preservative, and one or more of the following: a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative that specifically prevents mold, and a fragrance.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is a liquid wipe formulation. This formulation is used primarily in a feminine wipe. The wipe formulation has an anti-irritant agent, a pH adjuster, narriely citric acid, and at least one preservative.
The anti-irritant agent used in the present wipe formulation has been effective to clean, refresh and prevent further feminine itching. The anti-irritant agent is preferably one or more of the following: local anesthetics, analgesics, anesthetics, antipruitics, astringents, hydrocortisone preparations, keratolytics or any combinations thereof. The local anesthetics that can be used in the present invention include benzocaine, benzyl alcohol, dibucaine, dibucaine HCI, Dyclonine HCI, Lidocaine, Pramoxine HCI, Tetracaine, Tetracaine HCI, or any combinations thereof.
The anti-irritant agent is preferably present in an amount from about .1 wt%
up to about 50 wt% of the total weight of the liquid, wipe formulation. More preferably, the anti-irritant agent is preferably present in an amount about 9 wt% of the total weight of the liquid, wipe formulation.
When the anti-irritant agent is an anesthetic, it is preferably a mixture of the following local anesthetics, and preferably in the approximate amount, set forth below.
Local Anesthetics in percentage by wt (wt%) of the wipe formulation Benzocaine 5.0 - 20.0 Benzyl alcohol 1.0 - 4.0 Dibucaine 0.25 - 1.0 Dibucaine HCI 0.25 -1.0 Dyclonine HCI 0.5 - 1.0 Lidocaine 2.0 - 5.0 Pramoxine HCI 1.0 Tetracaine 0.5 - 1.0 Tetracaine HCI 0.5 - 1.0 The analgesic, anesthetic or antipruitic anti-irritant agents that can be used in the present wipe formulation include camphor, juniper tar, menthol or combinations thereof. When the anti-irritant agent is an analgesic, an anesthetic or an antipruitic, it is preferably in the following mixture, and in an approximate range, set forth below.
Analgesic, anesthetic and antipruitic in wt% of the wipe formulation Camphor 0.1 - 3.0 Juniper tar 1.0 - 5.0 .
Menthol 0.1 - 1.0 The astringents that can be used in the present wipe formulation include calamine, zinc oxide or any combination thereof. When the anti-irritant agent is an astringent, it is preferably in the following mixture, and preferably in the approximate range, set forth below.
Astringents in wt% of the wipe formulation Calamine 5.0 - 25.0 Zinc oxide 5.0 - 25.0 Witch hazel 1.0 - 50.0 1o The hydrocortisone preparations that can be used in the present wipe formulation include hydrocortisone, hydrocortisone acetate or any combination thereof. If the anti-irritant agent is a hydrocortisone preparation, it is preferably present in the following mixture, and preferably in the approximate range, set forth below.
Hydrocortisone preparations in wt% of the wipe formulation Hydrocortisone 0.25 - 0.5 Hydrocortisone acetate0.25 - 0.5 The keratolytics that can be used in the present wipe formulation include alcloxa, resorcinol or any combination thereof. When the anti-irritant agent is a keratolytic, it is preferably present the following mixture, and preferably in the approximate range, set forth below.
Keratolytics in wt% of the wipe formulation Alcloxa 0.2 - 2.0 Resorcinol 1.0 - 3.0 The second ingredient of the present wipe formulation is a pH
adjuster. The preferred pH adjuster is citric acid. Preferably, citric acid is present in an amount from about 0.01 wt% to about 1 wt% of the total weight of the liquid, wipe formulation. More preferably, the citric acid is present in an amount from about 0.05 wt% to about 0.5 wt%, and most preferably about 0.1 wt%, of the total weight of the wipe formulation. With the above amounts of pH adjuster, the wipe formulation is in a pH range from about 4.0 to about 6.0, and preferably from about 4.5 to about 5Ø
The present wipe formulation has at least one preservative. That preservative is preferably one or more of the following: sodium hydroxymethylglycinate, polyaminopropyl biguanide, quaternary ammonium compound, EDTA salt, EDTA fatty acid conjugate, alkanol especially ethanol, isopropyl alcohol, benzyl alcohol, paraben, sorbate, urea derivative, and isothiazolinone, or any combination thereof. The preferred preservative is sodium hydroxymethylglycinate. The preservative is 2 0 preferably present in an amount from about 0.2 wt% to about 2 wt%, and more preferably about 0.5 wt%, of the total weight of the wipe formulation.
In one embodiment of the present invention, the liquid wipe formulation has an anti-irritant agent, a pH adjuster, namely citric acid, and at least one preservative. In another embodiment of the present invention, the wipe formulation has the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, and one or more of the following ingredients:
a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance.
In yet another embodiment of the present invention, the liquid wipe formulation includes the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, a humectant, a surfactant, ~a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance.
The humectant used in a wipe of the present invention is preferably one or more of the following: glycerol, propylene glycol, sorbitol urea, amino acid, polyol and other compounds with hygroscopic properties, or any combination thereof. The preferred humectant is propylene glycol.
The humectant is preferably present in an amount from about 0.1 wt% up to about 2 wt% of the total weight of the liquid, wipe formulation. More preferably, the humectant is present in an amount about 0.5 wt%.
The surfactant that can be used in a wipe formulation of the present invention is preferably one or more of the following: alkylamido alkylamine, quaternary ammonium compound, phosphorus derivative, amphoteric imidazoline derivative, fatty sulfosuccinate ester and amide, ethoxylated sorbitan ester, betaine, alkoxylated alcohol, alkyl ether sulfate, disodium cocoamphodiacetate, cocamidopropyl betaine, PEG-80 glyceryl cocoate/PEG-30 glyceryl cocoate, decyl polyglucose, or any combinations thereof. The preferred surfactant is disodium cocoamphodiacetate. The surfactant is preferably present in an amount greater than about 0 to about 1 wt% of the total weight of the liquid, wipe formulation. More preferably, the surfactant is present in an amount about 0.10 wt% of the total weight of the wipe formulation.
The skin conditioning agent used in an embodiment of-the present wipe formulation is preferably one or more of the following: botanical extract including aloe vera gel, ester including tocopherol acetate (vitamin E acetate), quaternary ammonium compound, asymmetrical carbonate, N-substituted carboxamide, urea or phosphine oxide, organic salt, or any combination thereof. The skin conditioning agent is preferably present in an amount greater than about 0 wt% up to about 1.25 wt% of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.02 wt% of the wipe formulation. The preferred skin conditioning agents are aloe vera gel and tocopheryl acetate. When used, aloe vera gel is preferably present in an amount greater than about 0 to about 1 wt% of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt%. When used, tocopheryl acetate (vitamin E acetate) is preferably present in an amount greater than about 0 to about 1.0 wt% of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt% of the wipe 1 o formulation.
The emulsifying agent used in a wipe formulation of the present invention is any one or more of the following: sorbitan, alkoxylated fatty alcohol, alkylpolyglycoside, soap, alkyl sulfate, monoalkyl and dialkyl phosphate, alkyl sulphonate, acyl isothionate, or any combinations thereof.
The preferred emulsifying agent is polysorbate 20. The emulsifying agent is preferably present in an amount greater than about 0 wt% to about 1 wt% of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.25 wt% of the wipe formulation.
The chelating agent that can be used in a present wipe formulation 2 o is preferably one or more of the following: disodium EDTA
(ethylenediamine tetraacetate), ethylene-diamine-tetra-acetic acid, (ethylenedioxy)-diethylene-dinitrilo-tetra-acetic acid, salicylaldoxime, quinolinol, triethylenetetramine, or any combinations thereof. The preferred chelating agent is disodium EDTA. The chelating agent is preferably 2 5 present in an amount greater than about 0 wt% up to about 0.2 wt% of the total weight of the liquid, wipe formulation. More preferably, the chelating agent is present in an amount about 0.1 wt% of the wipe formulation.
A wipe formulation of the present invention may include a second preservative that is specifically present to prevent mold. The preferred 3 o second preservative is potassium sorbate. The second preservative is preferably present in an amount from about 0.1 wt% to about 0.3 wt% of the total weight of the liquid, wipe formulation. More preferably, the second preservative is present in an amount about 0.14 wt% of the wipe formulation.
A wipe formulation of the present invention may include a fragrance.
Any conventional fragrance that is mild and does not adversely affect sensitive areas for females, or other adults, may be used. Preferably, the fragrance is present in an amount greater than about 0 wt% up to about 0.5 wt%, and more preferably about 0.05 wt%, of the total weight of the liquid, wipe formulation.
The one example of the subject liquid wipe formulation is listed in 1 o Table 1 in weight percents, along with acceptable ranges.
Table 1 Ingredient Subject FormulationRanges (wt%) (wt"/o) Water QS QS
Witch Hazel 9 1 -50 Propylene Glycol 0.5 0.1 - 2 Disodium Cocoamphodiacetate0.1 0 -1 Tocopheryl Acetate (Vitamin0.01 0 -1 E
Acetate) Aloe Vera Gel 0.01 0 - 1 Fragrance 0.05 0 - 0.5 Polysorbate 20 0.25 0 - 0.5 Preservative 0.5 0.2 - 2 Disodium EDTA 0.1 0 - 0.2 Potassium Sorbate 0.14 0.1 - 0.3 Citric Acid 0.1 0.01 -1 The wipe formulations of the present invention have therapeutic benefits. In addition, they prevent or minimize skin irritation and itching.
Moreover, each of the wipe formulations of the present invention is mild.
The wipe formulations of the present invention may be used as a feminine wipe and, in particular, prevent or minimize feminine itching.
It should be understood that the foregoing description is only illustrative of the present invention. Various alternatives and modifications 2 o can be devised by those skilled in the art without departing from the invention. Accordingly, the present invention is intended to embrace all such alternatives, modifications and variances that fall within the scope of the appended claims.
U.S. Patent No. 5,804,203 to Hahn et al. is directed to a topical composition for reducing skin irritation in animals comprising an irritant ingredient and an anti-irritant amount of aqueous-soluble strontium cation.
U.S. Patent No. 4,772,501 to Johnson et al. is directed to a wet wipe product having a fibrous wipe, a liquid preservative composition, and an 2 0 enclosure for the fibrous wipe and the liquid preservative composition.
The liquid preservative composition consists essentially of: (a) a mixture of citric acid and sorbic acid as the preservative component; (b) water; and (c) optional ingredients selected from the group consisting of skin moisturizers and fragrance compounds.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a mild formulation for use in a wipe.
It is another object of the present invention to provide a mild wipe formulation that has an anti-irritant agent.
It is a further object of the present invention to provide such a mild wipe formulation that prevents or minimizes skin irritation and itching especially feminine itching.
These and other objects and advantages of the present invention are achieved by a mild wipe formulation that comprises an anti-irritant agent, citric acid and at least one preservative. In one embodiment of the present invention, the wipe formulation comprises an anti-irritant agent, a pH adjuster, namely citric acid, at least one preservative, and one or more of the following: a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative that specifically prevents mold, and a fragrance.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is a liquid wipe formulation. This formulation is used primarily in a feminine wipe. The wipe formulation has an anti-irritant agent, a pH adjuster, narriely citric acid, and at least one preservative.
The anti-irritant agent used in the present wipe formulation has been effective to clean, refresh and prevent further feminine itching. The anti-irritant agent is preferably one or more of the following: local anesthetics, analgesics, anesthetics, antipruitics, astringents, hydrocortisone preparations, keratolytics or any combinations thereof. The local anesthetics that can be used in the present invention include benzocaine, benzyl alcohol, dibucaine, dibucaine HCI, Dyclonine HCI, Lidocaine, Pramoxine HCI, Tetracaine, Tetracaine HCI, or any combinations thereof.
The anti-irritant agent is preferably present in an amount from about .1 wt%
up to about 50 wt% of the total weight of the liquid, wipe formulation. More preferably, the anti-irritant agent is preferably present in an amount about 9 wt% of the total weight of the liquid, wipe formulation.
When the anti-irritant agent is an anesthetic, it is preferably a mixture of the following local anesthetics, and preferably in the approximate amount, set forth below.
Local Anesthetics in percentage by wt (wt%) of the wipe formulation Benzocaine 5.0 - 20.0 Benzyl alcohol 1.0 - 4.0 Dibucaine 0.25 - 1.0 Dibucaine HCI 0.25 -1.0 Dyclonine HCI 0.5 - 1.0 Lidocaine 2.0 - 5.0 Pramoxine HCI 1.0 Tetracaine 0.5 - 1.0 Tetracaine HCI 0.5 - 1.0 The analgesic, anesthetic or antipruitic anti-irritant agents that can be used in the present wipe formulation include camphor, juniper tar, menthol or combinations thereof. When the anti-irritant agent is an analgesic, an anesthetic or an antipruitic, it is preferably in the following mixture, and in an approximate range, set forth below.
Analgesic, anesthetic and antipruitic in wt% of the wipe formulation Camphor 0.1 - 3.0 Juniper tar 1.0 - 5.0 .
Menthol 0.1 - 1.0 The astringents that can be used in the present wipe formulation include calamine, zinc oxide or any combination thereof. When the anti-irritant agent is an astringent, it is preferably in the following mixture, and preferably in the approximate range, set forth below.
Astringents in wt% of the wipe formulation Calamine 5.0 - 25.0 Zinc oxide 5.0 - 25.0 Witch hazel 1.0 - 50.0 1o The hydrocortisone preparations that can be used in the present wipe formulation include hydrocortisone, hydrocortisone acetate or any combination thereof. If the anti-irritant agent is a hydrocortisone preparation, it is preferably present in the following mixture, and preferably in the approximate range, set forth below.
Hydrocortisone preparations in wt% of the wipe formulation Hydrocortisone 0.25 - 0.5 Hydrocortisone acetate0.25 - 0.5 The keratolytics that can be used in the present wipe formulation include alcloxa, resorcinol or any combination thereof. When the anti-irritant agent is a keratolytic, it is preferably present the following mixture, and preferably in the approximate range, set forth below.
Keratolytics in wt% of the wipe formulation Alcloxa 0.2 - 2.0 Resorcinol 1.0 - 3.0 The second ingredient of the present wipe formulation is a pH
adjuster. The preferred pH adjuster is citric acid. Preferably, citric acid is present in an amount from about 0.01 wt% to about 1 wt% of the total weight of the liquid, wipe formulation. More preferably, the citric acid is present in an amount from about 0.05 wt% to about 0.5 wt%, and most preferably about 0.1 wt%, of the total weight of the wipe formulation. With the above amounts of pH adjuster, the wipe formulation is in a pH range from about 4.0 to about 6.0, and preferably from about 4.5 to about 5Ø
The present wipe formulation has at least one preservative. That preservative is preferably one or more of the following: sodium hydroxymethylglycinate, polyaminopropyl biguanide, quaternary ammonium compound, EDTA salt, EDTA fatty acid conjugate, alkanol especially ethanol, isopropyl alcohol, benzyl alcohol, paraben, sorbate, urea derivative, and isothiazolinone, or any combination thereof. The preferred preservative is sodium hydroxymethylglycinate. The preservative is 2 0 preferably present in an amount from about 0.2 wt% to about 2 wt%, and more preferably about 0.5 wt%, of the total weight of the wipe formulation.
In one embodiment of the present invention, the liquid wipe formulation has an anti-irritant agent, a pH adjuster, namely citric acid, and at least one preservative. In another embodiment of the present invention, the wipe formulation has the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, and one or more of the following ingredients:
a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance.
In yet another embodiment of the present invention, the liquid wipe formulation includes the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, a humectant, a surfactant, ~a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance.
The humectant used in a wipe of the present invention is preferably one or more of the following: glycerol, propylene glycol, sorbitol urea, amino acid, polyol and other compounds with hygroscopic properties, or any combination thereof. The preferred humectant is propylene glycol.
The humectant is preferably present in an amount from about 0.1 wt% up to about 2 wt% of the total weight of the liquid, wipe formulation. More preferably, the humectant is present in an amount about 0.5 wt%.
The surfactant that can be used in a wipe formulation of the present invention is preferably one or more of the following: alkylamido alkylamine, quaternary ammonium compound, phosphorus derivative, amphoteric imidazoline derivative, fatty sulfosuccinate ester and amide, ethoxylated sorbitan ester, betaine, alkoxylated alcohol, alkyl ether sulfate, disodium cocoamphodiacetate, cocamidopropyl betaine, PEG-80 glyceryl cocoate/PEG-30 glyceryl cocoate, decyl polyglucose, or any combinations thereof. The preferred surfactant is disodium cocoamphodiacetate. The surfactant is preferably present in an amount greater than about 0 to about 1 wt% of the total weight of the liquid, wipe formulation. More preferably, the surfactant is present in an amount about 0.10 wt% of the total weight of the wipe formulation.
The skin conditioning agent used in an embodiment of-the present wipe formulation is preferably one or more of the following: botanical extract including aloe vera gel, ester including tocopherol acetate (vitamin E acetate), quaternary ammonium compound, asymmetrical carbonate, N-substituted carboxamide, urea or phosphine oxide, organic salt, or any combination thereof. The skin conditioning agent is preferably present in an amount greater than about 0 wt% up to about 1.25 wt% of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.02 wt% of the wipe formulation. The preferred skin conditioning agents are aloe vera gel and tocopheryl acetate. When used, aloe vera gel is preferably present in an amount greater than about 0 to about 1 wt% of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt%. When used, tocopheryl acetate (vitamin E acetate) is preferably present in an amount greater than about 0 to about 1.0 wt% of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt% of the wipe 1 o formulation.
The emulsifying agent used in a wipe formulation of the present invention is any one or more of the following: sorbitan, alkoxylated fatty alcohol, alkylpolyglycoside, soap, alkyl sulfate, monoalkyl and dialkyl phosphate, alkyl sulphonate, acyl isothionate, or any combinations thereof.
The preferred emulsifying agent is polysorbate 20. The emulsifying agent is preferably present in an amount greater than about 0 wt% to about 1 wt% of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.25 wt% of the wipe formulation.
The chelating agent that can be used in a present wipe formulation 2 o is preferably one or more of the following: disodium EDTA
(ethylenediamine tetraacetate), ethylene-diamine-tetra-acetic acid, (ethylenedioxy)-diethylene-dinitrilo-tetra-acetic acid, salicylaldoxime, quinolinol, triethylenetetramine, or any combinations thereof. The preferred chelating agent is disodium EDTA. The chelating agent is preferably 2 5 present in an amount greater than about 0 wt% up to about 0.2 wt% of the total weight of the liquid, wipe formulation. More preferably, the chelating agent is present in an amount about 0.1 wt% of the wipe formulation.
A wipe formulation of the present invention may include a second preservative that is specifically present to prevent mold. The preferred 3 o second preservative is potassium sorbate. The second preservative is preferably present in an amount from about 0.1 wt% to about 0.3 wt% of the total weight of the liquid, wipe formulation. More preferably, the second preservative is present in an amount about 0.14 wt% of the wipe formulation.
A wipe formulation of the present invention may include a fragrance.
Any conventional fragrance that is mild and does not adversely affect sensitive areas for females, or other adults, may be used. Preferably, the fragrance is present in an amount greater than about 0 wt% up to about 0.5 wt%, and more preferably about 0.05 wt%, of the total weight of the liquid, wipe formulation.
The one example of the subject liquid wipe formulation is listed in 1 o Table 1 in weight percents, along with acceptable ranges.
Table 1 Ingredient Subject FormulationRanges (wt%) (wt"/o) Water QS QS
Witch Hazel 9 1 -50 Propylene Glycol 0.5 0.1 - 2 Disodium Cocoamphodiacetate0.1 0 -1 Tocopheryl Acetate (Vitamin0.01 0 -1 E
Acetate) Aloe Vera Gel 0.01 0 - 1 Fragrance 0.05 0 - 0.5 Polysorbate 20 0.25 0 - 0.5 Preservative 0.5 0.2 - 2 Disodium EDTA 0.1 0 - 0.2 Potassium Sorbate 0.14 0.1 - 0.3 Citric Acid 0.1 0.01 -1 The wipe formulations of the present invention have therapeutic benefits. In addition, they prevent or minimize skin irritation and itching.
Moreover, each of the wipe formulations of the present invention is mild.
The wipe formulations of the present invention may be used as a feminine wipe and, in particular, prevent or minimize feminine itching.
It should be understood that the foregoing description is only illustrative of the present invention. Various alternatives and modifications 2 o can be devised by those skilled in the art without departing from the invention. Accordingly, the present invention is intended to embrace all such alternatives, modifications and variances that fall within the scope of the appended claims.
Claims (31)
1. A liquid formulation for a wipe comprising an anti-irritant agent, citric acid, and at least one preservative, said irritant agent being present in an amount of about 9 wt% of the total weight of the formulation, wherein the formulation has therapeutic benefits.
2. The formulation of claim 1, wherein said anti-irritant agent is selected from the group consisting of anesthetic, analgesic, antipruitic, astringent, hydrocortisone preparation, keratolytic, and any combinations thereof.
3. The formulation of claim 1, wherein said anti-irritant agent is at least one local anesthetic selected from the group consisting of:
benzocaine, benzyl alcohol, dibucaine, dibucaine HCI, Dyclonine HCI, Lidocaine, Pramoxine HCI, Tetracaine, Tetracaine HCI, and any combinations thereof.
benzocaine, benzyl alcohol, dibucaine, dibucaine HCI, Dyclonine HCI, Lidocaine, Pramoxine HCI, Tetracaine, Tetracaine HCI, and any combinations thereof.
4. A liquid formulation for a wipe comprising an anti-irritant agent, citric acid, and at least one preservative, wherein said anti-irritant agent is selected from the group consisting of camphor, juniper tar, menthol, and any combinations thereof.
5. The formulation of claim 1, wherein said anti-irritant agent is at least one hydrocortisone derivative selected from the group consisting of hydrocortisone, hydrocortisone acetate, and any combination thereof.
6. A liquid formulation for a wipe comprising an anti-irritant agent, citric acid, and at least one preservative, wherein said anti-irritant agent is selected from the group consisting of alcloxa, resorcinol, and any combination thereof.
7. The formulation of claim 1, wherein said anti-irritant agent is at least one astringent selected from the group consisting of witch hazel, calamine, zinc oxide, and any combinations thereof.
8. The formulation of claim 1, wherein said anti-irritant agent is witch hazel.
9. (Cancelled)
10. (Cancelled)
11. The formulation of Claim 1, wherein said citric acid is present in an amount from 0.01 wt% to 1 wt% of the total weight of the formulation.
12. The formulation of claim 1, wherein the formulation is in a pH
range from about 4.0 to about 6Ø
range from about 4.0 to about 6Ø
13. The formulation of claim 1, wherein said at least one preservative is present in an amount from about 0.2 wt% to about 2 wt% of the total weight of the formulation.
14. The formulation of claim 1, wherein said at least one preservative is sodium hydroxymethylglycinate.
15. The formulation of claim 1, further comprising a humectant selected from the group consisting of glycerol, propylene glycol, sorbitol urea, amino acid, polyol, and any combinations thereof.
16. The formulation of claim 15, wherein said humectant is present in an amount from about 0.1 wt% to about 2 wt% of the total weight of the formulation.
17. The formulation of claim 1, further comprising a surfactant selected from the group consisting of alkylamido alkylamine, quaternary ammonium compound, phosphorus derivative, amphoteric imidazoline derivative, fatty sulfosuccinate ester and amide, ethoxylated sorbitan ester, betaine, alkoxylated alcohol, alkyl ether sulfate, disodium cocoamphodiacetate, cocamidopropyl betaine, PEG-80 glyceryl cocoate/PEG-30 glyceryl cocoate, decyl polyglucose, and any combinations thereof
18. The formulation of claim 17, wherein said surfactant is present in an amount greater than about 0 wt% to about 1 wt% of the total weight of the formulation.
19. The formulation of claim 1, further comprising a skin conditioning agent selected from the group consisting of botanical extract, ester, quaternary ammonium compound, asymmetrical carbonate, N-substituted carboxamide, urea, phosphine oxide, organic salt, and any combinations thereof.
20. The formulation of claim 19, wherein the skin conditioning agent is in an amount greater than about 0 wt% up to about 1.25 wt% of the total weight of the formulation.
21. The formulation of claim 1, further comprising an emulsifying agent selected from the group consisting of: sorbitan, alkoxylated fatty alcohol, alkylpolyglycoside, soap, alkyl sulfate, monoalkyl and dialkyl phosphate, alkyl sulphonate, acyl isothionate, and any combinations thereof.
22. The formulation of claim 21, wherein the emulsifying agent is in an amount greater than about 0 wt% to about 1 wt% of the total weight of the formulation.
23. The formulation of claim 1, further comprising a second preservative that combats mold.
24. The formulation of claim 23, wherein said second preservative is in an amount from about 0.1 wt% to about 0.3 wt% of the total weight of the formulation.
25. The formulation of claim 23, wherein said second preservative is potassium sorbate.
26. The formulation of claim 1, further comprising a chelating agent selected from the group consisting of disodium EDTA, ethylene-diamine-tetra-acetic acid, (ethylenedioxy)-diethlyene-dinitrilo-tetra-acetic acid, salicylaldoxime, quinolinol, triethylenetetramine, and any combinations thereof.
27. The formulation of claim 26, wherein said chelating agent is present in an amount greater than about 0 wt% up to about 0.2 wt% of the total weight of the formulation.
28. The formulation of claim 1, further comprising a fragrance.
29. (Cancelled)
30. The formulation of claim 4, wherein the camphor is present in an amount of about 0.1 wt% to about 3.0 wt% if the anti-irritant agent is camphor; wherein the juniper tar is present in an amount of about 1.0 wt%
to about 5.0 wt% if the anti-irritant agent is juniper tar; and wherein the menthol is present in an amount of about 0.1 wt% to about 1.0 wt% if the anti-irritant agent is menthol.
to about 5.0 wt% if the anti-irritant agent is juniper tar; and wherein the menthol is present in an amount of about 0.1 wt% to about 1.0 wt% if the anti-irritant agent is menthol.
31. The formulation of claim 6, wherein the alcloxa is present in an amount of about 0.2 wt% to about 2.0 wt% if the anti-irritant agent is alcloxa; and wherein the resorcinol is present in an amount of about 1.0 wt% to about 3.0 wt% if the anti-irritant agent is resorcinol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/968,200 | 2001-10-01 | ||
US09/968,200 US6737068B2 (en) | 2001-10-01 | 2001-10-01 | Wipe formulation |
PCT/US2002/030352 WO2003028600A1 (en) | 2001-10-01 | 2002-09-25 | Wipe formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2462510A1 CA2462510A1 (en) | 2003-04-10 |
CA2462510C true CA2462510C (en) | 2010-08-24 |
Family
ID=25513896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2462510A Expired - Fee Related CA2462510C (en) | 2001-10-01 | 2002-09-25 | Wipe formulation |
Country Status (5)
Country | Link |
---|---|
US (2) | US6737068B2 (en) |
AU (1) | AU2002337677B2 (en) |
CA (1) | CA2462510C (en) |
MX (1) | MXPA04003088A (en) |
WO (1) | WO2003028600A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2844455B1 (en) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES |
US20060051428A1 (en) * | 2004-09-03 | 2006-03-09 | Nelson Ayala | Aspartame and citrate flavored phosphate salt laxative |
US20060062832A1 (en) * | 2004-09-20 | 2006-03-23 | Lopes John A | Sanitizing wipes with microbicidal properties cross-reference to related applications |
US7604997B2 (en) * | 2005-01-18 | 2009-10-20 | The United States Of America As Represented By The Department Of Health And Human Services | Wipes and methods for removal of metal contamination from surfaces |
US20060171971A1 (en) * | 2005-02-01 | 2006-08-03 | The Procter & Gamble Company | Composition for wet wipes containing a non-irritating skin health benefit ingredient and the process for making |
US20070082061A1 (en) * | 2005-10-07 | 2007-04-12 | Nelson Ayala | Reduction of saltiness with sweeteners |
US7985429B2 (en) | 2006-03-03 | 2011-07-26 | C. B. Fleet Company, Inc. | Flavored colonic cleansing system |
EP1998742A2 (en) * | 2006-03-08 | 2008-12-10 | Nuviance, INC. | Transdermal drug delivery compositions and topical compositions for application on the skin |
US7998510B2 (en) * | 2006-08-17 | 2011-08-16 | C. B. Fleet Company, Inc. | Low dose colonic cleansing system |
EP1980241B1 (en) | 2007-04-04 | 2015-10-14 | Mibelle AG | Wet wipes with vitex agnus castus extract for feminine personal care |
WO2008133868A1 (en) * | 2007-04-23 | 2008-11-06 | Safe N' Simple | Stoma wipe and adhesive remover and method |
US20080260806A1 (en) * | 2007-04-23 | 2008-10-23 | Risa Miller | Personal hygiene compositions and methods |
US8481480B1 (en) * | 2012-04-30 | 2013-07-09 | Uyen T. Lam | Anti-adherent formulation including a quaternary ammonium compound and a fatty alcohol |
US8648027B2 (en) | 2012-07-06 | 2014-02-11 | The Clorox Company | Low-VOC cleaning substrates and compositions comprising a cationic biocide |
CN105324157B (en) | 2013-06-27 | 2019-01-29 | 宝洁公司 | Personal care composition and product |
CN105764392B (en) | 2013-12-03 | 2019-11-19 | 金伯利-克拉克环球有限公司 | Wet wipe for personal nursing |
RU2646489C2 (en) * | 2013-12-20 | 2018-03-05 | Пфайзер Инк. | Pre-moistened wipes for use in treatment of anorectal irritations and disorders |
US9096821B1 (en) | 2014-07-31 | 2015-08-04 | The Clorox Company | Preloaded dual purpose cleaning and sanitizing wipe |
US10264788B2 (en) | 2015-12-30 | 2019-04-23 | Carefusion 2200, Inc. | Antimicrobial wipe |
US10975341B2 (en) | 2017-09-18 | 2021-04-13 | The Clorox Company | Cleaning wipes having particular MABDF characteristics |
US10973386B2 (en) | 2017-09-18 | 2021-04-13 | The Clorox Company | Cleaning wipes system having particular performance characteristics |
US10973385B2 (en) | 2017-09-18 | 2021-04-13 | The Clorox Company | Cleaning wipes having particular pore volume distribution characteristics |
US10982177B2 (en) | 2017-09-18 | 2021-04-20 | The Clorox Company | Cleaning wipes with particular lotion retention and efficacy characteristics |
US20200337971A1 (en) * | 2018-01-15 | 2020-10-29 | Sanit Technologies Llc | Anti-microbial soap |
US11472164B2 (en) | 2018-12-21 | 2022-10-18 | The Clorox Company | Multi-layer substrates comprising sandwich layers and polyethylene |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2565887A (en) | 1946-06-21 | 1951-08-28 | Ivers Lee Co | Sheathed flexible sheet |
US3414927A (en) | 1966-10-10 | 1968-12-10 | Gurdon S. Worcester | Composite web for treating human tissue |
US3786615A (en) | 1972-11-13 | 1974-01-22 | Pfizer | Process for preparing pre-moistened antimicrobial towels |
US4309469A (en) | 1977-08-22 | 1982-01-05 | Scott Paper Company | Flushable binder system for pre-moistened wipers wherein an adhesive for the fibers of the wipers interacts with ions contained in the lotion with which the wipers are impregnated |
US4383986A (en) | 1981-08-17 | 1983-05-17 | Ortho Pharmaceutical Corporation | Hemorrhoidal compositions |
US4615937A (en) | 1985-09-05 | 1986-10-07 | The James River Corporation | Antimicrobially active, non-woven web used in a wet wiper |
US4737405A (en) | 1985-09-30 | 1988-04-12 | James River Corporation | Binder catalyst for an antimicrobially active, non-woven web |
IL78566A (en) | 1986-04-22 | 1989-07-31 | Porat Amir | Towelette |
US4781974A (en) | 1986-04-23 | 1988-11-01 | James River Corporation | Antimicrobially active wet wiper |
US4865221A (en) | 1986-07-30 | 1989-09-12 | Kimberly-Clark Corporation | Wet wipe and wipe dispensing arrangement |
US4741944A (en) | 1986-07-30 | 1988-05-03 | Kimberly-Clark Corporation | Wet wipe and wipe dispensing arrangement |
DE3630392C1 (en) | 1986-09-06 | 1988-02-11 | Rhodia Ag | Process for the production of consolidated nonwovens |
US4732797A (en) | 1987-02-27 | 1988-03-22 | James River Corporation | Wet wiper natural acid preservation system |
US4772501A (en) | 1987-02-27 | 1988-09-20 | James River Corporation | Wet wiper natural acid preservation system |
US6033679A (en) | 1998-04-27 | 2000-03-07 | The Procter & Gamble Company | Uncomplexed cyclodextrin compositions for odor control |
US5141803A (en) * | 1988-06-29 | 1992-08-25 | Sterling Drug, Inc. | Nonwoven wipe impregnating composition |
US4941995A (en) | 1988-07-05 | 1990-07-17 | Scott Paper Company | Natural preservative composition for wet wipes |
US4904524A (en) | 1988-10-18 | 1990-02-27 | Scott Paper Company | Wet wipes |
US5049440A (en) | 1989-07-28 | 1991-09-17 | The James River Corporation | Wet wiper natural acid and salt preservative composition |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5219646A (en) | 1990-05-11 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Polyester blends and their use in compostable products such as disposable diapers |
US5152996A (en) | 1990-12-10 | 1992-10-06 | Eastman Kodak Company | Nonwoven wipes impregnated with an aqueous solution of a zinc acetate peroxide and a surfactant |
US5215759A (en) | 1991-10-01 | 1993-06-01 | Chanel, Inc. | Cosmetic composition |
US5449763A (en) | 1991-10-10 | 1995-09-12 | Henkel Corporation | Preparation of alkylpolyglycosides |
AU3136593A (en) | 1991-11-22 | 1993-06-15 | Richardson-Vicks Inc. | Combined personal cleansing and moisturizing compositions |
US5256417A (en) | 1992-01-31 | 1993-10-26 | Air Products And Chemicals, Inc. | Water dispersible towelette impregnated with non-aqueous lotion formulations |
TW311085B (en) | 1993-03-18 | 1997-07-21 | Dymon Inc | |
US5447930A (en) * | 1993-05-06 | 1995-09-05 | Warner-Lambert Company | Topical anesthetic compositions |
US5635469A (en) | 1993-06-10 | 1997-06-03 | The Procter & Gamble Company | Foaming cleansing products |
US5407958A (en) * | 1993-07-30 | 1995-04-18 | Beauticontrol Cosmetics, Inc. | Therapeutic skin composition |
US5512199A (en) | 1993-11-02 | 1996-04-30 | Becton Dickinson And Company | Hand wipe solution |
JPH09507073A (en) | 1993-12-23 | 1997-07-15 | ザ、プロクター、エンド、ギャンブル、カンパニー | Antibacterial wipe composition |
JPH09510185A (en) | 1993-12-23 | 1997-10-14 | ザ、プロクター、エンド、ギャンブル、カンパニー | Tissue moisturizing and antimicrobial composition |
JPH10500868A (en) | 1994-02-28 | 1998-01-27 | インクライン・テクノロジーズ・インコーポレーテッド | Method and system for cleansing skin |
ATE171639T1 (en) | 1994-06-29 | 1998-10-15 | Ecolab Inc | CLEANING COMPOSITION AND PH-CONTROLLED METHOD FOR SEPARATING WASTEWATER USING AN AMPHOTERIC CARBOXYLATE AND A CATIONIC DESTABILIZING COMPOSITION |
US5607678A (en) | 1994-08-24 | 1997-03-04 | The Procter & Gamble Company | Mild shower gel composition comprising unique thickener system which imparts improved lathering properties and modified rinse feel |
US5534265A (en) | 1994-08-26 | 1996-07-09 | The Procter & Gamble Company | Thickened nonabrasive personal cleansing compositions |
CN1159159A (en) | 1994-08-26 | 1997-09-10 | 普罗克特和甘保尔公司 | Personal cleansing compositions |
US5507968A (en) | 1994-12-14 | 1996-04-16 | Minnesota Mining And Manufacturing Company | Cleansing articles with controlled detergent release and method for their manufacture |
US5716625A (en) | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5804203A (en) | 1994-12-21 | 1998-09-08 | Cosmederm Technologies | Topical product formulations containing strontium for reducing skin irritation |
WO1996020712A1 (en) * | 1994-12-30 | 1996-07-11 | American Home Products Corporation | Clear non-alcoholic hydrocortisone solutions |
US5648083A (en) | 1995-02-10 | 1997-07-15 | The Procter & Gamble Company | Personal care compositions and wipe products containing the compositions |
US5629081A (en) | 1995-03-31 | 1997-05-13 | Kimberly-Clark Tissue Corporation | Premoistened, flushable, disposable and biodegradable wet wipes |
JP3669758B2 (en) | 1995-06-15 | 2005-07-13 | ユニ・チャーム株式会社 | Lid device |
US5665364A (en) | 1995-07-24 | 1997-09-09 | The Procter & Gamble Company | Compositions for topical delivery of active ingredients |
ZA966814B (en) | 1995-08-18 | 1998-02-12 | Colgate Palmolive Co | Clear cosmetic gel composition. |
US5753246A (en) | 1995-11-20 | 1998-05-19 | Peters; Marlin W. | Packaged germicidal towelette, sanitation kit and method for promoting hygiene |
US6015816A (en) | 1996-02-29 | 2000-01-18 | The Research Foundation Of State University Of New York | Antimicrobial compositions |
US6001344A (en) | 1996-03-06 | 1999-12-14 | Lever Brothers Company | Liquid cleansing compositions comprising xanthan gum and cross-linked polyacrylic acid polymers for enhanced suspension of large droplet oils |
US5736128A (en) | 1996-05-14 | 1998-04-07 | Isp Investments Inc. | Cosmetic composition for rejuvenation of skin without skin irritation |
CZ13599A3 (en) | 1996-07-16 | 1999-05-12 | The Procter & Gamble Company | Use of combination of surface-active agents, chelate forming agents and essential oils for effective disinfection |
US5897856A (en) * | 1996-10-24 | 1999-04-27 | The Procter & Gamble Company | Methods and compositions for reducing body odor |
US5939050A (en) | 1997-04-04 | 1999-08-17 | Optiva Corp. | Antimicrobial compositions |
US5968539A (en) | 1997-06-04 | 1999-10-19 | Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria |
US5942214A (en) | 1997-06-09 | 1999-08-24 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins and perfume |
US6015547A (en) | 1997-10-27 | 2000-01-18 | Church & Dwight Co., Inc. | Stable solution of zinc ions and bicarbonate and/or carbonate ions |
US5993792A (en) | 1997-11-13 | 1999-11-30 | Tiro Industries Incorporated | System for customized hair products containing surfactants |
US6042839A (en) | 1998-03-09 | 2000-03-28 | Color Access, Inc. | Powder compositions |
US5915394A (en) | 1998-08-10 | 1999-06-29 | Rickard; Peter | Fragrance towelette |
-
2001
- 2001-10-01 US US09/968,200 patent/US6737068B2/en not_active Expired - Lifetime
-
2002
- 2002-09-25 CA CA2462510A patent/CA2462510C/en not_active Expired - Fee Related
- 2002-09-25 WO PCT/US2002/030352 patent/WO2003028600A1/en active IP Right Grant
- 2002-09-25 MX MXPA04003088A patent/MXPA04003088A/en active IP Right Grant
- 2002-09-25 AU AU2002337677A patent/AU2002337677B2/en not_active Ceased
-
2004
- 2004-01-08 US US10/753,797 patent/US20040151763A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003028600B1 (en) | 2003-09-18 |
US20030072789A1 (en) | 2003-04-17 |
AU2002337677B2 (en) | 2003-04-14 |
US6737068B2 (en) | 2004-05-18 |
US20040151763A1 (en) | 2004-08-05 |
WO2003028600A1 (en) | 2003-04-10 |
MXPA04003088A (en) | 2004-07-08 |
CA2462510A1 (en) | 2003-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2462510C (en) | Wipe formulation | |
AU2002337677A1 (en) | Wipe formulation | |
EP0906086B1 (en) | Skin wash composition | |
US5858383A (en) | Methods and compositions for topical treatment of ectoparasites | |
US20020151446A1 (en) | Mild foaming cleanser composition | |
CA2142419A1 (en) | Composition | |
US4224319A (en) | Antiseptic composition for topical application to the skin | |
US6566408B1 (en) | Aqueous surfactant compositions of monoalkyl phosphate ester salts and amphoteric surfactants | |
CA2248993A1 (en) | Cleansing and moisturizing surfactant compositions | |
US6641826B2 (en) | Wipe with improved cleansing | |
AU2001270161A1 (en) | Wipe with improved cleansing | |
USRE32300E (en) | Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use thereof | |
US20120142572A1 (en) | Low irritancy cleansing compositions | |
CA2145968A1 (en) | Topical antipruritic composition | |
JP2001240547A (en) | Inhibitor of pollinosis | |
JPH06340520A (en) | Acyl isethionate skin cleansing composition containing selected betaine | |
JPH0542998B2 (en) | ||
US20200390673A1 (en) | Composition for neutralizing or reducing effects of self-defense sprays | |
CN112675107A (en) | Anorectal wet tissue and preparation method thereof | |
JPH0548800B2 (en) | ||
WO2001010991A1 (en) | Aqueous surfactant compositions of monoalkyl phosphate ester salts and amphoteric surfactants | |
JPS62285996A (en) | Low irritant detergent composition | |
WO1997025965A1 (en) | Mild shampoo composition | |
Marks Jr et al. | Safety Assessment of Alkyl Betaines as Used in Cosmetics | |
JPS62151497A (en) | Low irritant detergent composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180925 |